Portal hypertension reversibility with treatment of underlying liver disease

Paul Y. Kwo, Marco A. Lacerdo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cirrhosis is the end-stage manifestation of chronic hepatitis with the most common causes of chronic hepatitis in developed countries being related to hepatitis B, hepatitis C, nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease. With more advanced cirrhosis, the development of portal hypertension occurs that leads to clinical decompensation. With improvement in therapies for hepatitis B and C, we have seen regression of fibrosis and even cirrhosis. However, there are limited data on reversal of portal hypertension. This review examines the direct and indirect evidence that we will be able to see regression of portal hypertension in those with cirrhosis.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalCurrent Hepatitis Reports
Volume14
Issue number3
DOIs
StatePublished - Jul 22 2015

Fingerprint

Portal Hypertension
Liver Diseases
Fibrosis
Chronic Hepatitis
Hepatitis C
Hepatitis B
Alcoholic Liver Diseases
Developed Countries

Keywords

  • Cirrhosis
  • Hepatitis B
  • Hepatitis C
  • Nonalcoholic steatohepatitis
  • Portal hypertension

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Portal hypertension reversibility with treatment of underlying liver disease. / Kwo, Paul Y.; Lacerdo, Marco A.

In: Current Hepatitis Reports, Vol. 14, No. 3, 22.07.2015, p. 219-224.

Research output: Contribution to journalArticle

Kwo, Paul Y. ; Lacerdo, Marco A. / Portal hypertension reversibility with treatment of underlying liver disease. In: Current Hepatitis Reports. 2015 ; Vol. 14, No. 3. pp. 219-224.
@article{5a104da2942f4f24b9ff093b2b045c9b,
title = "Portal hypertension reversibility with treatment of underlying liver disease",
abstract = "Cirrhosis is the end-stage manifestation of chronic hepatitis with the most common causes of chronic hepatitis in developed countries being related to hepatitis B, hepatitis C, nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease. With more advanced cirrhosis, the development of portal hypertension occurs that leads to clinical decompensation. With improvement in therapies for hepatitis B and C, we have seen regression of fibrosis and even cirrhosis. However, there are limited data on reversal of portal hypertension. This review examines the direct and indirect evidence that we will be able to see regression of portal hypertension in those with cirrhosis.",
keywords = "Cirrhosis, Hepatitis B, Hepatitis C, Nonalcoholic steatohepatitis, Portal hypertension",
author = "Kwo, {Paul Y.} and Lacerdo, {Marco A.}",
year = "2015",
month = "7",
day = "22",
doi = "10.1007/s11901-015-0275-5",
language = "English (US)",
volume = "14",
pages = "219--224",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Portal hypertension reversibility with treatment of underlying liver disease

AU - Kwo, Paul Y.

AU - Lacerdo, Marco A.

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Cirrhosis is the end-stage manifestation of chronic hepatitis with the most common causes of chronic hepatitis in developed countries being related to hepatitis B, hepatitis C, nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease. With more advanced cirrhosis, the development of portal hypertension occurs that leads to clinical decompensation. With improvement in therapies for hepatitis B and C, we have seen regression of fibrosis and even cirrhosis. However, there are limited data on reversal of portal hypertension. This review examines the direct and indirect evidence that we will be able to see regression of portal hypertension in those with cirrhosis.

AB - Cirrhosis is the end-stage manifestation of chronic hepatitis with the most common causes of chronic hepatitis in developed countries being related to hepatitis B, hepatitis C, nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease. With more advanced cirrhosis, the development of portal hypertension occurs that leads to clinical decompensation. With improvement in therapies for hepatitis B and C, we have seen regression of fibrosis and even cirrhosis. However, there are limited data on reversal of portal hypertension. This review examines the direct and indirect evidence that we will be able to see regression of portal hypertension in those with cirrhosis.

KW - Cirrhosis

KW - Hepatitis B

KW - Hepatitis C

KW - Nonalcoholic steatohepatitis

KW - Portal hypertension

UR - http://www.scopus.com/inward/record.url?scp=84942323048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942323048&partnerID=8YFLogxK

U2 - 10.1007/s11901-015-0275-5

DO - 10.1007/s11901-015-0275-5

M3 - Article

AN - SCOPUS:84942323048

VL - 14

SP - 219

EP - 224

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 3

ER -